Bydureon (exenatide extended-release) injection [product information]
However, it can reduce appetite and may lead to changes in eating habits
While traditional GLP-1 drugs personal injury lawsuits target pharmaceutical manufacturers, claims involving compounded versions may focus on compounding pharmacies or prescribing physicians
doi: 10.3389/fragi.2026.1743142 Received 10 November 2025 Revised 08 January 2026 Accepted 13 January 2026 Published 04 February 2026 Volume 7 - 2026 Edited by Edio Maldonado, University of Chile, Chile Reviewed by Jas Sara, Mayo Clinic, United States Kazuo Yudoh, St
Changes in protein consumption, including reducing protein levels but remaining within the safe levels, may alter plasma glutathione synthesis levels contributing to a reduction in antioxidant capacity